Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer. [electronic resource]

By:

Yu, Yong

Contributor(s):

Qi, Jingjing
Xiong, Jieyi
Jiang, Liping
Cui, Di
He, Junlin
Chen, Ping
Li, Lianjie
Wu, Chenjie
Ma, Tonghui
Shao, Su
Wang, Jianjun
Yu, Dansong
Zhou, Bing
Huang, Dongsheng
Schmitt, Clemens A
Tao, Ran

Producer: 20200114Description: 761-777 p. digitalISSN:

1838-7640

Subject(s):

Animals
Antibiotics, Antineoplastic -- administration & dosage
Apoptosis -- drug effects
Cancer Survivors
Cell Line, Tumor
Cellular Senescence -- drug effects
DNA Methylation
DNA, Neoplasm -- metabolism
Doxorubicin -- administration & dosage
Drug Delivery Systems
Enhancer of Zeste Homolog 2 Protein -- antagonists & inhibitors
Epigenesis, Genetic
Female
Gene Expression Regulation, Neoplastic -- drug effects
Humans
Indazoles -- pharmacology
Mice
Mice, Nude
Mixed Function Oxygenases -- antagonists & inhibitors
Proto-Oncogene Proteins -- antagonists & inhibitors
Pyridones -- pharmacology
Triple Negative Breast Neoplasms -- genetics
Xenograft Model Antitumor Assays

Online resources:

Available from publisher's website

In: Theranostics vol. 9

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

There are no comments on this title.

Browse results Close

Back to results

1 [Activation of latent TGF-beta. A required mechanism for vascular integrity].
by Gleizes, P E
2 Labeling of basic fibroblast growth factor with digoxigenin: a nonradioactive probe for biochemical and cytological applications.
by Gleizes, P E
3 Basic fibroblast growth factor (FGF-2) internalization through the heparan sulfate proteoglycans-mediated pathway: an ultrastructural approach.
by Gleizes, P E
4 Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor.
by Jonca, F
5 Basic fibroblast growth factor (FGF-2) is addressed to caveolae after binding to the plasma membrane of BHK cells.
by Gleizes, P E
6 Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta.
by Nunes, I
7 Assembly and functional organization of the nucleolus: ultrastructural analysis of Saccharomyces cerevisiae mutants.
by Trumtel, S
8 Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1.
by Gleizes, P E
9 Latent transforming growth factor-beta: structural features and mechanisms of activation.
by Munger, J S
10 Plasminogen/plasminogen activator and growth factor activation.
by Rifkin, D B
11 Nog2p, a putative GTPase associated with pre-60S subunits and required for late 60S maturation steps.
by Saveanu, C
12 Structure and activation of the large latent transforming growth factor-Beta complex.
by Nunes, I
13 Processing of 20S pre-rRNA to 18S ribosomal RNA in yeast requires Rrp10p, an essential non-ribosomal cytoplasmic protein.
by Vanrobays, E
14 TGF-beta latency: biological significance and mechanisms of activation.
by Gleizes, P E
15 Structure and activation of the large latent transforming growth factor-beta complex.
by Nunes, I
16 Ultrastructural localization of rRNA shows defective nuclear export of preribosomes in mutants of the Nup82p complex.
by Gleizes, P E
17 Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells.
by Rudd, P M
18 The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway.
by Bailly, A

Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.

APA

Yu Y., Qi J., Xiong J., Jiang L., Cui D., He J., Chen P., Li L., Wu C., Ma T., Shao S., Wang J., Yu D., Zhou B., Huang D., Schmitt C. A. & Tao R. (20200114). Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer. : Theranostics.

Chicago

Yu Yong, Qi Jingjing, Xiong Jieyi, Jiang Liping, Cui Di, He Junlin, Chen Ping, Li Lianjie, Wu Chenjie, Ma Tonghui, Shao Su, Wang Jianjun, Yu Dansong, Zhou Bing, Huang Dongsheng, Schmitt Clemens A and Tao Ran. 20200114. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer. : Theranostics.

Harvard

Yu Y., Qi J., Xiong J., Jiang L., Cui D., He J., Chen P., Li L., Wu C., Ma T., Shao S., Wang J., Yu D., Zhou B., Huang D., Schmitt C. A. and Tao R. (20200114). Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer. : Theranostics.

MLA

Yu Yong, Qi Jingjing, Xiong Jieyi, Jiang Liping, Cui Di, He Junlin, Chen Ping, Li Lianjie, Wu Chenjie, Ma Tonghui, Shao Su, Wang Jianjun, Yu Dansong, Zhou Bing, Huang Dongsheng, Schmitt Clemens A and Tao Ran. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer. : Theranostics. 20200114.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC